Answers are grounded in this paper and cite their sources.
Pharmacovigilance study reveals hematological and thrombotic adverse events with immune checkpoint inhibitors, indicating the need for clinical vigilance.
Hematological and thrombotic AEs associated with ICI therapy show notable reporting frequencies in FAERS. Combination regimens demonstrated stronger reporting signals for certain events. These AEs frequently showed early reporting and notable mortality proportions, highlighting the importance of clinical vigilance. Further studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: